Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

This study is testing whether adding the targeted antibody drug nimotuzumab (which blocks a growth signal called EGFR) to the standard treatment of induction chemotherapy plus chemoradiation improves outcomes for patients with locally advanced nasopharyngeal cancer (cancer at the back of the nasal cavity). **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with locally advanced nasopharyngeal carcinoma (stage III-IV, non-keratinizing type) - Your general health is good (ECOG score 0-1) - Your blood counts and organ function are within acceptable ranges - The primary tumor site can be measured **You may NOT be eligible if...** - You have had prior surgery to the primary tumor (other than a diagnostic biopsy), prior chemotherapy, or prior anti-EGFR treatment - You have another active cancer - You have serious heart or lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.